Quality of life in patients receiving medicines for prostate cancer: What do clinicians think is important?

Emma Dunlop, Steven Karlsson-Brown, Jennifer Laskey, Marion Bennie, Kelly Baillie, Julie Clarke

Research output: Contribution to journalMeeting abstract

Abstract

Objectives: In addition to clinical outcomes it is increasingly recognised that Patient Reported Outcomes (PROMs) are a useful measure of benefit of cancer medicines. Although verbally discussed in clinic appointments, the impact cancer medicines have on quality of life (QoL) is not consistently documented in routine clinical practice. Recent studies have shown that utilising QoL tools can have a positive impact on clinician decision-making and improve patient outcomes.1,2 Many PROMs tools exist, but there is limited evidence on which may best support assessing the impact cancer medicines have on QoL as part of routine clinical care.
LanguageEnglish
Pages54-55
Number of pages2
JournalJournal of Oncology Pharmacy Practice
Volume24
Issue number8
Publication statusPublished - 1 Dec 2018
Event21st Annual BOPA Symposium - Birmingham, United Kingdom
Duration: 12 Oct 201814 Oct 2018

Fingerprint

Prostatic Neoplasms
Quality of Life
Neoplasms
Decision Making
Appointments and Schedules
Patient Reported Outcome Measures

Keywords

  • PROMs
  • cancer medicines
  • pharmacy
  • quality of life

Cite this

Dunlop, Emma ; Karlsson-Brown, Steven ; Laskey, Jennifer ; Bennie, Marion ; Baillie, Kelly ; Clarke, Julie. / Quality of life in patients receiving medicines for prostate cancer : What do clinicians think is important?. In: Journal of Oncology Pharmacy Practice. 2018 ; Vol. 24, No. 8. pp. 54-55.
@article{fa6fa0eb74044716a42c62d3da939ceb,
title = "Quality of life in patients receiving medicines for prostate cancer: What do clinicians think is important?",
abstract = "Objectives: In addition to clinical outcomes it is increasingly recognised that Patient Reported Outcomes (PROMs) are a useful measure of benefit of cancer medicines. Although verbally discussed in clinic appointments, the impact cancer medicines have on quality of life (QoL) is not consistently documented in routine clinical practice. Recent studies have shown that utilising QoL tools can have a positive impact on clinician decision-making and improve patient outcomes.1,2 Many PROMs tools exist, but there is limited evidence on which may best support assessing the impact cancer medicines have on QoL as part of routine clinical care.",
keywords = "PROMs, cancer medicines, pharmacy, quality of life",
author = "Emma Dunlop and Steven Karlsson-Brown and Jennifer Laskey and Marion Bennie and Kelly Baillie and Julie Clarke",
year = "2018",
month = "12",
day = "1",
language = "English",
volume = "24",
pages = "54--55",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
number = "8",

}

Quality of life in patients receiving medicines for prostate cancer : What do clinicians think is important? / Dunlop, Emma; Karlsson-Brown, Steven; Laskey, Jennifer; Bennie, Marion; Baillie, Kelly; Clarke, Julie.

In: Journal of Oncology Pharmacy Practice, Vol. 24, No. 8, 01.12.2018, p. 54-55.

Research output: Contribution to journalMeeting abstract

TY - JOUR

T1 - Quality of life in patients receiving medicines for prostate cancer

T2 - Journal of Oncology Pharmacy Practice

AU - Dunlop, Emma

AU - Karlsson-Brown, Steven

AU - Laskey, Jennifer

AU - Bennie, Marion

AU - Baillie, Kelly

AU - Clarke, Julie

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Objectives: In addition to clinical outcomes it is increasingly recognised that Patient Reported Outcomes (PROMs) are a useful measure of benefit of cancer medicines. Although verbally discussed in clinic appointments, the impact cancer medicines have on quality of life (QoL) is not consistently documented in routine clinical practice. Recent studies have shown that utilising QoL tools can have a positive impact on clinician decision-making and improve patient outcomes.1,2 Many PROMs tools exist, but there is limited evidence on which may best support assessing the impact cancer medicines have on QoL as part of routine clinical care.

AB - Objectives: In addition to clinical outcomes it is increasingly recognised that Patient Reported Outcomes (PROMs) are a useful measure of benefit of cancer medicines. Although verbally discussed in clinic appointments, the impact cancer medicines have on quality of life (QoL) is not consistently documented in routine clinical practice. Recent studies have shown that utilising QoL tools can have a positive impact on clinician decision-making and improve patient outcomes.1,2 Many PROMs tools exist, but there is limited evidence on which may best support assessing the impact cancer medicines have on QoL as part of routine clinical care.

KW - PROMs

KW - cancer medicines

KW - pharmacy

KW - quality of life

UR - http://www.bopawebsite.org/content/annual-symposium-2018

M3 - Meeting abstract

VL - 24

SP - 54

EP - 55

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 8

ER -